Pharmaceutical manufacturers of Furosemide

Sanofi is a global healthcare leader committed to improving lives around the world. With a strong focus on research and development, Sanofi strives to transform scientific innovation into healthcare solutions that address unmet medical needs. The company's extensive portfolio spans prescription medicines, vaccines, consumer healthcare products, and biopharmaceuticals, covering a wide range of therapeutic areas, including diabetes, cardiovascular disease, oncology, immunology, rare diseases, and vaccines.

TAPI stands as the primary global provider of active pharmaceutical ingredients (APIs). With the most extensive range of over 370 high-caliber API products in the industry, we cater to almost 1,000 clients across more than 100 nations. Operating as an independent division under Teva Pharmaceutical Industries, our legacy in the generic API sector spans over 80 years. Situated in close proximity to Tel Aviv, Israel, TAPI boasts a workforce of over 5,000 professionals spread across 19 facilities worldwide. Our cutting-edge manufacturing plants are situated in Italy, Hungary, the Czech Republic, Croatia, Israel, India, China, Mexico, and several other locations.

Teva's roots are deeply rooted in the land of Israel since 1901 in Jerusalem. That's when the first chapter was written in the long and unique history of the company, which slowly transformed from a small drug trading house to the largest generic company in the world, improving the health of millions of patients in Israel and around the world every day.

Kalintis Healthcare envisions creating a health-conscious Pharmaceuticals Company focused on promoting Wellness for Humanity. The company employs advanced in-house technology to maintain high quality standards in the manufacturing of Speciality Chemicals, Advanced Intermediates, and Active Pharmaceutical Ingredients through Chemical Process R&D, followed by commercial-scale production to cater to global customers. The APIs produced are intended for the USA market, while all other products are targeted for international distribution. There are plans to submit at least three DMF filings annually.

OLON Group is a prominent worldwide firm specializing in the creation and manufacture of active pharmaceutical ingredients for CDMO and Generics. It serves as a dependable and preferred partner for the pharmaceutical, biotech, and specialty ingredients sectors. With a 2021 turnover of 580 million dollars, OLON provides 300 APIs for the Generic market. The company benefits from a workforce of 2,300 employees, including a highly skilled R&D team of over 300 individuals. This enables OLON to offer comprehensive integrated packages and services to facilitate the full development of APIs, leveraging extensive expertise in both Chemical and Biological processes, all within a full cGMP and regulatory framework. OLON holds approximately 160 active US DMFs and 79 granted CoS. OLON's headquarters is located in Rodano, near Milan, Italy, and it operates 11 manufacturing facilities - 8 in Italy, 1 in Spain, 1 in the USA, and 1 in India. These facilities are designed in accordance with the most stringent international standards. Additionally, OLON has 3 branch offices in Hamburg (Germany), Florham Park, NJ (USA), and Shanghai (China).

For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others.

Euroapi focuses on revolutionizing active component solutions to sustainably fulfill the demands of clients and patients globally. As a prominent figure in active pharmaceutical ingredients, we possess a comprehensive portfolio of around 200 products, encompassing a wide range of technologies, and are constantly developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO). Our 3,350 employees are driven by the commitment to improving access to essential therapies and promoting health

SMS Lifesciences India Limited, headquartered in Hyderabad, India, is a research-driven company with over three decades of experience. It is a public listed leading API manufacturer, supplying to major generic and innovator firms. With a focus on APIs, the company operates four state-of-the-art facilities and provides quality alternative manufacturing solutions to multinational companies for their contract research and manufacturing needs. The company has multiple manufacturing facilities supporting a wide range and capacity of APIs and Intermediates.

Fisvi is a distinguished Italian company with a proud heritage in the manufacturing and innovation sectors. Specializing in advanced materials and cutting-edge solutions, Fisvi offers a wide range of products tailored to meet the demands of various industries, including construction, automotive, and industrial applications. Their product lineup includes high-quality insulation materials, adhesives, sealants, and other specialized components designed to enhance performance and durability.

Sri Krishna Pharmaceuticals Ltd (SKPL), established in 1974, started life as a pioneer in the bulk manufacture of acetaminophen (Paracetamol) for the domestic Indian market. Today, the company is a vertically integrated bulk manufacturer of multiple first-line-of-defence APIs, PFIs and finished dosage drugs. Paracetamol is still very important to the company and the company remains one of the largest manufacturers in the world. The role of Indian bulk drug manufacturers in the global pharma supply chain has evolved greatly, with SKPL increasing its presence in the synthesis of bulk APIs, direct compression, intermediate and finished dosage products.

Inabata France, a division of the Inabata Group, was established in 1990 to export chemical and medicinal products to Japan. It purchased Pharmasynthèse in 2006. Inabata-Pharmasynthèse provides an extensive range of services, including procurement, production, and innovation of raw materials for the pharmaceutical and beauty sectors. It delivers pharmaceutical and beauty components to Europe, Japan, and other regions worldwide. Its specialty lies in the manufacture of high-quality chemicals. Manufacturing is conducted at its versatile facility in St Pierre-Les-Elbeuf, France, ranging from pilot to commercial scales. The plant operates under GMP conditions.

Over the last 100 years, Celanese has evolved from a small experiment in a backyard shed in Switzerland to a global technology and specialty materials company with leading businesses in key geographic regions. The Dreyfus brothers had a vision for the company that included discovering market needs and finding ways to fulfill them. By honing their ability to diversify and adapt, the brothers were able to expand the company to one of the largest chemical manufacturers in the world. With a focus on safety, innovation, productivity, culture, performance and results, Celanese is positioned to achieve significant future growth and deliver exceptional results for all stakeholders. Our history below highlights the milestones that formed Celanese.

The ACIC Group operates as a comprehensive pharmaceutical and fine chemical company, producing and supplying active pharmaceutical ingredients, offering contract manufacturing services, process development, regulatory services, clinical services, and finished dosage forms from cGMP and FDA inspected facilities. Its proven track record and dedication make it an excellent choice for pharmaceutical projects, with the ability to anticipate market and regulatory trends in regulated and semi-regulated markets. The ACIC service relationship is designed to be adaptable to individual needs, allowing for full customization. Additionally, ACIC offers multilingual communication and translation services in French, German, Spanish, Italian, Portuguese, Mandarin, and other languages. ACIC's Open World Service aims to provide more efficient solutions by offering a wider range of global choices, supporting clients in the transition from molecule to market. The company provides solutions in areas such as fine chemicals, marketing and sales, process research, formulation, site transfer, CRO services, electronic CTD format, sales and acquisition of facilities, process development, pilot scale-up, process optimization, manufacturing scale-up, production validation, global regulatory submission, regulatory interpretation, and patent application.